Therefore, the present study suggests that the development of portal hypertension with LS ≥ 4 kPa in ACLD may also trigger a decrease in IGF-1, and these multiple factors may form the initial pathogenesis of muscle mass loss associated with liver disease. This evidence concerns the gene IGF1 and liver disorder.